Adv Medical Solutns. - Application for Admission
|
|
|
Advanced Medical Solutions Group plc
("AMS", the "Company" or the "Group")
Application for Admission
Winsford,
The block listing application relates to New Ordinary Shares to be issued from time to time pursuant to the exercise of share options under the Company's existing schemes as follows:
|
Scheme |
No. of New Ordinary Shares |
|
Employee Share Purchase Plan (ESPP) |
2,000,000 |
|
Company Share Option Plan (CSOP) |
200,000 |
|
Unapproved Executive Share Option Scheme (ESOS) |
200,000 |
|
Long-Term Incentive Plan (LTIP) |
4,000,000 |
|
Group Share Option Plan (GSOP) |
4,000,000 |
In addition to the above, application has been made for 2,000,000 New Ordinary Shares has been applied for under the Employee Share Purchase Plan, previously named the Deferred Share Bonus Scheme.
An application has been made with respect to a new
When issued, the New Ordinary Shares will be credited as fully paid and will rank pari passu in all respects with the existing ordinary shares of
It is expected that admission will become effective for the Ordinary Shares on 15 September 2025.
- End -
For further information, please visit www.admedsol.com or contact:
|
Advanced Medical Solutions Group plc |
Tel: +44 (0) 1606 545508 |
|
|
|
|
|
|
|
Optimum Strategic Communications |
Tel: +44 (0) 20 3709 5700 |
|
Mary Clark / |
AMS@optimumcomms.com |
|
|
|
|
Investec Bank PLC (NOMAD & Broker) |
Tel: +44 (0) 20 7597 5970 |
|
|
|
|
|
|
|
Berenberg (Joint Broker) |
Tel: +44 (0) 20 3207 7800 |
|
Toby Flaux / Detlir Elezi / |
|
About Advanced Medical Solutions Group plc - see www.admedsol.com
AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8®, LIQUIFIX™, Peters Surgical, Ifabond, Vitalitec and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made seven acquisitions: Sealantis, an Israeli developer of innovative internal sealants, Biomatlante, a French developer and manufacturer of surgical biomaterials,
AMS's products, manufactured in the
-
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE